Global Breast Cancer Monoclonal Antibodies Market Growth 2024 , Forecast To 2033

The breast cancer monoclonal antibodies market size has grown strongly in recent years, from $18.97 billion in 2023 to $20.18 billion in 2024 at a compound annual growth rate (CAGR) of 6.4%. This growth is attributed to the rising prevalence of breast cancer, increasing awareness of breast cancer monoclonal antibodies, growing clinical efficacy, and patient demand. It is expected to continue growing, reaching $27.8 billion in 2028 at a CAGR of 8.3%. This expansion is driven by emerging targets, biosimilars, combination therapies, and factors such as global incidence and aging population, alongside personalized medicine. Major trends in the forecast period include advances in early breast cancer detection, immunotherapy integration, liquid biopsies, companion diagnostics, adjuvant and neoadjuvant therapies, and long-term survivorship support.